• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World Journal of Oncology >Circulating Levels of Agouti-Related Peptide in Endometrial Cancer Survivors
【24h】

Circulating Levels of Agouti-Related Peptide in Endometrial Cancer Survivors

机译：子宫内膜癌幸存者中痛风相关肽的循环水平

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Recently, it has been reported that central administration of agouti-related peptide (AgRP) might have protective effect against cachexia development in tumor-bearing mice. In this study, we determined whether the disease-free endometrial cancer survivors present with different plasma AgRP levels than controls and whether there was an association with the duration of the disease-free interval.Methods: The total of 53 endometrial cancer survivors was enrolled in the study along with 93 healthy control women of similar age. Fasting blood samples were obtained and AgRP plasma levels determined using ELISA-based methodology. Results: The AgRP plasma levels were significantly higher in the cases than in the controls; AgRP levels were the lowest in obese control women (77.4 ± 19.8 pg/ml); on the contrary, the AgRP plasma levels were highest in non-obese cancer survivors (100.5 ± 21.12 pg/ml). Moreover, we observed significant differences in AgRP levels between the endometrial cancer survivors and the control subjects [p (for comparison of the cases and the controls) = 0.002]. In the regression modeling, AgRP was significantly associated with the BMI as well as the case-control status, and the case-control differences in AgRP levels retained their statistical significance also after adjustment for BMI. Conclusions: Disease-free endometrial cancer survivors who did not develop cachexia during their treatment as well as post-treatment period present with significantly higher AgRP levels than the control population, independently on their BMI and menopausal status which could be indicative of the protective effect of circulating AgRP against cachexia development in endometrial cancer. doi:10.4021/wjon385w
机译：背景：最近，有报道称，与足骨相关肽（AgRP）的中央给药可能对荷瘤小鼠的恶病质发展具有保护作用。在这项研究中，我们确定了无病子宫内膜癌幸存者的血浆AgRP水平是否与对照组不同，并且与无病间隔的持续时间是否相关。方法：共有53名子宫内膜癌幸存者参加了研究。这项研究与93名年龄相似的健康对照女性一起进行。获得空腹血液样品，并使用基于ELISA的方法确定AgRP血浆水平。结果：病例中的AgRP血浆水平显着高于对照组。肥胖对照女性的AgRP水平最低（77.4±19.8 pg / ml）;相反，在非肥胖的癌症幸存者中，AgRP血浆水平最高（100.5±21.12 pg / ml）。此外，我们观察到子宫内膜癌幸存者与对照组之间的AgRP水平存在显着差异[p（用于病例与对照组的比较）= 0.002]。在回归模型中，AgRP与BMI以及病例对照状态显着相关，并且在调整BMI之后，AgRP水平的病例对照差异仍保持其统计学意义。结论：无病子宫内膜癌幸存者在治疗期间和治疗后均未出现恶病质，其AgRP水平明显高于对照人群，而与他们的BMI和更年期状态无关，这可能表明其的保护作用。循环AgRP对抗子宫内膜癌恶病质发展。 doi：10.4021 / wjon385w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号